Compare VMC & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMC | IQV |
|---|---|---|
| Founded | 1909 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2B | 35.1B |
| IPO Year | 2007 | 2013 |
| Metric | VMC | IQV |
|---|---|---|
| Price | $271.65 | $240.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $323.17 | $227.13 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 18.39 | 4.67 |
| EPS | 1.26 | ★ 1.61 |
| Revenue | $7,781,900,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $1.85 | $6.77 |
| Revenue Next Year | $6.22 | $5.89 |
| P/E Ratio | $220.75 | ★ $149.84 |
| Revenue Growth | 6.38 | ★ 41.60 |
| 52 Week Low | $252.35 | $154.50 |
| 52 Week High | $331.09 | $251.36 |
| Indicator | VMC | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 64.22 |
| Support Level | $268.10 | $222.95 |
| Resistance Level | $300.91 | $247.52 |
| Average True Range (ATR) | 7.34 | 7.13 |
| MACD | -0.41 | -0.72 |
| Stochastic Oscillator | 27.09 | 81.64 |
Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2024, Vulcan sold 219.9 million tons of aggregates, 13.6 million tons of asphalt mix, and 3.6 million cubic yards of ready-mix. As of Dec. 31, 2024, the company had 16.5 billion tons of aggregate reserves.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.